Abstract
Digoxin has been widely used in the treatment of heart failure for more than 200 years, yet it remains controversial. This review looks back at the role of digoxin in light of clinical trials, particularly the DIG trial, and contrasts it with ivabradine in the SHIFT trial. Digoxin has been shown to be effective at all heart rates; it is an inexpensive drug and safe in patients with heart failure. Its use should therefore not be restricted in patients in sinus rhythm, and its position as a last-choice option in the treatment of heart failure should be reconsidered.